Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous AMBTX-01 (Neridronate) for the Treatment of Complex Regional Pain Syndrome Type 1

NCT07857733 is registered in ClinicalTrials.gov with Ambros Therapeutics, Inc. as lead sponsor.

NCT NCT07857733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07857733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous AMBTX-01 (Neridronate) for the Treatment of Complex Regional Pain Syndrome Type 1
Lead sponsor
Ambros Therapeutics, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
February 15, 2029
Enrollment
135 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

complex regional pain syndrome type i